Search
Trimethaphan
go.drugbank.com/drugs/DB01116ApprovedInvestigationalA nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery.
Amifampridine
go.drugbank.com/drugs/DB11640ApprovedThis leads to the reduction of the compound muscle action potential (CMAP) [A33863]. … ) enzymes (acetylator phenotype) and NAT2 genotype, which is subject to genetic variation [F272].
Temafloxacin
go.drugbank.com/drugs/DB01405ApprovedWithdrawnTemafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. … It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three
Reviparin
go.drugbank.com/drugs/DB09259ApprovedReviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin.
Lenograstim
go.drugbank.com/drugs/DB13144ApprovedWithdrawnLenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.
Loxoprofen
go.drugbank.com/drugs/DB09212ApprovedInvestigationalLoxoprofen is a propionic acid derivative non-steroidal anti-inflammatory drug. It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India, and as Oxeno in Argentina. A transdermal preparation ...
Capecitabine
go.drugbank.com/drugs/DB01101ApprovedInvestigationalCapecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Arsenic trioxide
go.drugbank.com/drugs/DB01169ApprovedInvestigationalArsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. … It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis.
Bezafibrate
go.drugbank.com/drugs/DB01393ApprovedInvestigationalAntilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.
Gefapixant
go.drugbank.com/drugs/DB15097Approvedor unexplained chronic cough (UCC) when no diagnosable cause for the cough can be determined. … [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601]